オプションチェーンは、Ensysce Biosciencesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Ensysce Biosciencesの市場センチメントを評価します。.

Ensysce Biosciences (NASDAQ:ENSC) 株価情報, オプションチェーン

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

On Thursday, Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported third-quarter revenue of $1.03 billion, a decrease of 4% on a reported basis or a 1% organic constant currency growth, in line with the consensus.
The animal health company reported adjusted EPS of $0.13, down 28% year over year, beating the consensus of $0.12.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40959456/elancos-dermatology-treatment-secures-fda-approval-for-itchy-dogs-analyst-highlight" rel="noreferrer noopener">Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy</a>
Pet Health revenue was $486 million, a decrease of 2% on a reported and constant currency basis, primarily driven by competitive pressure on certain products in the U.S. veterinary channel, competitive pressure in Australia, and supply volatility for vaccines in the U.S., partially offset by increased sales of new products and improved demand for retail parasiticide products in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41801193/elanco-animal-health-reports-third-quarter-2024-results" rel="noreferrer noopener">the U.S. and Europe</a>.
Farm Animal revenue fell 6% (+3% on constant currency) to $530 million, driven by a 3% increase in price. Volumes were flat, primarily driven by strength in U.S. cattle, led by Experior and Rumensin, and poultry sales in the U.S. and Europe, offset by lower demand for sheep products in Australia and planned volume declines from the strategic decision to change go-to-market models in certain countries, as well as the European recall of Kexxtone.
Gross profit was $538 million, or a margin of 52.2%, with a 220-basis point decline driven by higher inflation, unfavorable manufacturing performance, and product mix associated with the divested aqua business, partially offset by increased pricing.
Guidance: Elanco tightened its financial guidance for the full year 2024.
The company expects 2024 sales of $4.42 billion-$4.45 billion versus prior guidance of $4.41 billion-$4.46 billion and consensus of $4.43 billion.
The company expects 2024 adjusted EPS of $0.89-$0.95, compared to previous guidance of $0.88-$0.96 and the consensus of $0.92. Elanco has lowered expectations for U.S. Pet Health parasiticides.
Elanco expects fourth-quarter sales of $1 billion—$1.03 billion and adjusted EPS of $0.13-$0.18, compared to the consensus of $1.034 billion and $0.12, respectively.
"We are encouraged by the acceleration of constant currency sales growth from 1% in 2023 to the expected 3% organic constant currency growth in 2024. We see this accelerating further to mid-single digits in 2025 with increased sales from new products and a stabilizing base driving expected growth in both pet health and farm animal," said Todd Young, CFO of Elanco.
Price Action: ELAN stock is up 13.10% at $14.55 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41812662/krispy-kreme-falters-in-q3-earnings-miss-sales-slide-and-outlook-dims-post-insomnia-cookies-sale" target="_blank" rel="noreferrer noopener">Krispy Kreme Falters In Q3: Earnings Miss, Sales Slide, And Outlook Dims Post-Insomnia Cookies Sale</a></li>
</ul>
Image via Pexels

Analyst Color

Earnings

Large Cap

News

Guidance

Health Care

Analyst Ratings

Movers

General

ELAN

Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $92 to $55.

Price Target

APLS

Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $55

JP Morgan analyst Julia Qin maintains Guardant Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) with a Overweight and raises the price target from $48 to $50.

JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $50

RBC Capital analyst Brad Erickson maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Outperform and raises the price target from $66 to $74.

RBC Capital Maintains Outperform on Zillow Gr, Raises Price Target to $74

Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) reported third-quarter 2024 total net sales of $3.74 billion. That&#8217;s down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis compared to <a href="https://www.benzinga.com/topic/pharmaceuticals">third-quarter 2023 results</a>.
The company reported divestiture-adjusted operational net sales <a href="https://www.benzinga.com/pressreleases/24/11/n41803006/viatris-reports-third-quarter-financial-results-for-2024" target="_blank" rel="noreferrer noopener">growth across all segments</a>.
Brands net sales reflect the expansion of the company&#8217;s portfolio in emerging markets and JANZ, as well as strong growth in Europe and Greater China. This was partially offset by unfavorable channel dynamics in&nbsp;North America&nbsp;and the impact of government price regulations in&nbsp;Japan&nbsp;and&nbsp;Australia. Brand sales fell 7% to $2.36 billion.
Generic net sales reflect strong growth from new product performance in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio. Generic sales fell 2% to $1.38 billion.
The company generated approximately&nbsp;$133 million&nbsp;in new product revenues, primarily driven by Breyna, lisdexamfetamine, and other new products globally.
The company reported adjusted EPS of 75 cents, down 5% year over year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 68 cents</a>.
&#8220;We continue to make excellent progress executing on our debt paydown commitment and are on pace to achieve our long-term gross leverage target of ~3.0x by year-end,&#8221; said Viatris CFO Doretta Mistras. 
The company retired all of its 2025 and more than a quarter of its 2026 debt maturities, totaling approximately $1.9 billion in debt. That includes the make-whole call of its 2025 notes that settled in October.
Guidance:&nbsp;Viatris expects to deliver approximately&nbsp;$500 million&nbsp;to&nbsp;$600 million&nbsp;in new product revenues in 2024.
The company reaffirms 2024 sales of $14.6 billion – $15.1 billion&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38741136/weak-sales-from-lipitor-norvasc-hurt-viatris-q1-earnings-lowers-annual-forecast" rel="noreferrer noopener">versus </a>consensus of $14.80 billion.
The company expects 2024 adjusted EPS of $2.56-$2.71 compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40263060/us-drugmaker-viatris-q2-earnings-edge-out-analysts-expectation-on-strong-demand-for-branded-and-g" rel="noreferrer noopener">prior guidance of</a> $2.58–$2.73 and the consensus of $2.67.
Price Action: Viatris stock is up 13.9% at $13.22 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814727/dentsply-sirona-stock-sinks-on-dismal-2024-guidance-blames-macroeconomic-competitiv" target="_blank" rel="noreferrer noopener">Dentsply Sirona Stock Sinks On Dismal 2024 Guidance, Blames Macroeconomic, Competitive Pressures And Weakened Demand</a></li>
</ul>

Trading Ideas

VTRS

Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $100 to $105.

GILD

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $105

JP Morgan analyst Pinjalim Bora maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Overweight and raises the price target from $17 to $20.

FRSH

JP Morgan Maintains Overweight on Freshworks, Raises Price Target to $20

RBC Capital analyst Daniel Perlin maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Sector Perform and raises the price target from $76 to $105.

QTWO

RBC Capital Maintains Sector Perform on Q2 Holdings, Raises Price Target to $105

JP Morgan analyst John Ivankoe maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Overweight and raises the price target from $44 to $48.

BROS

JP Morgan Maintains Overweight on Dutch Bros, Raises Price Target to $48

Planet Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Thursday</a>.
The company <a target="_blank" href="https://www.prnewswire.com/news-releases/planet-fitness-inc-announces-third-quarter-2024-results-302298159.html" rel="noreferrer noopener">reported</a> third-quarter adjusted earnings per share of 64 cents beating the street view of 58 cents. Quarterly sales of $292.25 million (+5.3%) beat the analyst consensus estimate of $285.87 million.
System-wide same-club sales (formerly same-store sales) rose 4.3%, while system-wide sales grew to $1.2 billion, up from $1.1 billion last year.
Adjusted EBITDA increased by $11.2 million, rising to $123.1 million from $111.9 million in the same period last year.
During the period, 21 new Planet Fitness clubs were opened, comprising 12 franchisee-owned and 9 corporate-owned, bringing the total to 2,637 clubs as of September 30.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41816755/security-company-geos-q3-miss-lower-isap-participants-offset-by-strategic-contracts" rel="noreferrer noopener">Security Company GEO&#8217;s Q3 Miss: Lower ISAP Participants Offset By Strategic Contracts</a>
&#8220;During the quarter, I had the opportunity to address franchisees, club employees, and our team members at our franchisee conference,&#8221; said&nbsp;Colleen Keating, Chief Executive Officer. &#8220;The enthusiasm the franchisees showed was highly encouraging.&#8221;
The company highlighted reaching a significant milestone with a $15 price increase for its Classic Card membership for new members, marking the first such increase in over 25 years, and emphasizing the continued value offered to members.
The company exited the quarter with cash and marketable securities of&nbsp;$530.7 million, with inventory worth $4.858 billion. Long-term debt, net of current maturities as of the quarter end, totaled $2.152 billion.
Outlook: For the year ending December 31, the company is reiterating its expectations of approximately 120 to 130 new equipment placements in franchisee-owned locations and 140 to 150 system-wide new club openings.
The company now expects revenue to increase in the 8% to 9% range (previously 4% to 6%), adjusted EBITDA to rise by 8% to 9% (previously 7% to 9%), and adjusted net income per diluted share to increase by 11% to 12% (previously 7% to 9%).
Price Action: PLNT shares are trading higher by 12.2% to $94.99 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41814047" target="_blank" rel="noreferrer noopener">Halliburton Misses Q3 Expectations As North America Sales Falter; International Growth On The Horizon</a></li>
</ul>

Equities

Markets

PLNT

Planet Fitness Flexes Q3 Earnings Muscle With EPS Beat, Sales Growth, And First Classic Card Membership Price Hike In 25 Years

RBC Capital analyst Matthew McKellar maintains Rayonier Adv Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAM#NYSE">RYAM</a>) with a Outperform and raises the price target from $10 to $12.

RYAM

RBC Capital Maintains Outperform on Rayonier Adv Materials, Raises Price Target to $12

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$300.00</td>
<td>$33.2K</td>
<td>42.5K</td>
<td>197.0K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$210.00</td>
<td>$44.7K</td>
<td>4.9K</td>
<td>10.0K</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$15.00</td>
<td>$25.4K</td>
<td>5.0K</td>
<td>6.4K</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.00</td>
<td>$75.6K</td>
<td>48.0K</td>
<td>3.1K</td>
</tr>
<tr>
<td>W</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$45.00</td>
<td>$119.2K</td>
<td>15.9K</td>
<td>2.0K</td>
</tr>
<tr>
<td>TPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$48.00</td>
<td>$168.0K</td>
<td>726</td>
<td>703</td>
</tr>
<tr>
<td>ANF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$135.00</td>
<td>$195.0K</td>
<td>794</td>
<td>702</td>
</tr>
<tr>
<td>PLNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$27.6K</td>
<td>119</td>
<td>548</td>
</tr>
<tr>
<td>KSS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.00</td>
<td>$34.1K</td>
<td>2.4K</td>
<td>537</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.00</td>
<td>$25.5K</td>
<td>191</td>
<td>198</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bullish sentiment. It expires in 1 day(s) on November 8, 2024. Parties traded 74 contract(s) at a $300.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $33.2K, with a price of $450.0 per contract. There were 42589 open contracts at this strike prior to today, and today 197005 contract(s) were bought and sold. 
• Regarding AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we observe a call option trade with bullish sentiment. It expires in 106 day(s) on February 21, 2025. Parties traded 30 contract(s) at a $210.00 strike. The total cost received by the writing party (or parties) was $44.7K, with a price of $1490.0 per contract. There were 4982 open contracts at this strike prior to today, and today 10028 contract(s) were bought and sold. 
• For MBLY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), we notice a call option trade that happens to be bullish, expiring in 8 day(s) on November 15, 2024. This event was a transfer of 105 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $242.0 per contract. There were 5052 open contracts at this strike prior to today, and today 6455 contract(s) were bought and sold. 
• Regarding NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), we observe a call option sweep with bullish sentiment. It expires in 71 day(s) on January 17, 2025. Parties traded 1400 contract(s) at a $6.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $75.6K, with a price of $54.0 per contract. There were 48024 open contracts at this strike prior to today, and today 3128 contract(s) were bought and sold. 
• Regarding W (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>), we observe a call option sweep with bearish sentiment. It expires in 43 day(s) on December 20, 2024. Parties traded 547 contract(s) at a $45.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $119.2K, with a price of $218.0 per contract. There were 15977 open contracts at this strike prior to today, and today 2074 contract(s) were bought and sold. 
• Regarding TPR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), we observe a call option trade with bearish sentiment. It expires in 8 day(s) on November 15, 2024. Parties traded 400 contract(s) at a $48.00 strike. The total cost received by the writing party (or parties) was $168.0K, with a price of $420.0 per contract. There were 726 open contracts at this strike prior to today, and today 703 contract(s) were bought and sold. 
• Regarding ANF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>), we observe a call option trade with bearish sentiment. It expires in 8 day(s) on November 15, 2024. Parties traded 199 contract(s) at a $135.00 strike. The total cost received by the writing party (or parties) was $195.0K, with a price of $980.0 per contract. There were 794 open contracts at this strike prior to today, and today 702 contract(s) were bought and sold. 
• Regarding PLNT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>), we observe a call option sweep with neutral sentiment. It expires in 71 day(s) on January 17, 2025. Parties traded 114 contract(s) at a $100.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $243.0 per contract. There were 119 open contracts at this strike prior to today, and today 548 contract(s) were bought and sold. 
• For KSS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on November 15, 2024. This event was a transfer of 412 contract(s) at a $19.00 strike. This particular put needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $34.1K, with a price of $83.0 per contract. There were 2450 open contracts at this strike prior to today, and today 537 contract(s) were bought and sold. 
• Regarding XPEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), we observe a put option trade with bearish sentiment. It expires in 106 day(s) on February 21, 2025. Parties traded 94 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $25.5K, with a price of $272.0 per contract. There were 191 open contracts at this strike prior to today, and today 198 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMZN

MBLY

TSLA

XPEV

10 Consumer Discretionary Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Financials sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$36.00</td>
<td>$55.2K</td>
<td>83</td>
<td>3.7K</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$240.00</td>
<td>$29.0K</td>
<td>2.9K</td>
<td>3.5K</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$60.00</td>
<td>$25.2K</td>
<td>1.0K</td>
<td>2.3K</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$50.00</td>
<td>$52.3K</td>
<td>1.7K</td>
<td>2.3K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$44.00</td>
<td>$155.6K</td>
<td>7.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$85.00</td>
<td>$194.9K</td>
<td>12.0K</td>
<td>1.6K</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$130.00</td>
<td>$263.0K</td>
<td>782</td>
<td>1.3K</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$270.00</td>
<td>$58.8K</td>
<td>1.4K</td>
<td>688</td>
</tr>
<tr>
<td>FHN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$21.00</td>
<td>$28.4K</td>
<td>0</td>
<td>154</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$390.00</td>
<td>$28.1K</td>
<td>52</td>
<td>152</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TOST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), we observe a call option sweep with bullish sentiment. It expires in 8 day(s) on November 15, 2024. Parties traded 670 contract(s) at a $36.00 strike. This particular call needed to be split into 55 different trades to become filled. The total cost received by the writing party (or parties) was $55.2K, with a price of $83.0 per contract. There were 83 open contracts at this strike prior to today, and today 3735 contract(s) were bought and sold. 
• Regarding JPM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), we observe a put option trade with bullish sentiment. It expires in 1 day(s) on November 8, 2024. Parties traded 100 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $290.0 per contract. There were 2990 open contracts at this strike prior to today, and today 3504 contract(s) were bought and sold. 
• Regarding AFRM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on November 8, 2024. Parties traded 265 contract(s) at a $60.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $25.2K, with a price of $95.0 per contract. There were 1025 open contracts at this strike prior to today, and today 2377 contract(s) were bought and sold. 
• Regarding UPST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>), we observe a put option sweep with bullish sentiment. It expires in 8 day(s) on November 15, 2024. Parties traded 161 contract(s) at a $50.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $52.3K, with a price of $325.0 per contract. There were 1735 open contracts at this strike prior to today, and today 2353 contract(s) were bought and sold. 
• Regarding BAC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on November 8, 2024. Parties traded 1727 contract(s) at a $44.00 strike. This particular call needed to be split into 141 different trades to become filled. The total cost received by the writing party (or parties) was $155.6K, with a price of $90.0 per contract. There were 7064 open contracts at this strike prior to today, and today 2203 contract(s) were bought and sold. 
• Regarding PYPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>), we observe a call option sweep with bearish sentiment. It expires in 71 day(s) on January 17, 2025. Parties traded 619 contract(s) at a $85.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $194.9K, with a price of $315.0 per contract. There were 12069 open contracts at this strike prior to today, and today 1604 contract(s) were bought and sold. 
• For FUTU (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>), we notice a call option trade that happens to be bearish, expiring in 43 day(s) on December 20, 2024. This event was a transfer of 616 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $263.0K, with a price of $427.0 per contract. There were 782 open contracts at this strike prior to today, and today 1387 contract(s) were bought and sold. 
• Regarding COIN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), we observe a call option sweep with bearish sentiment. It expires in 22 day(s) on November 29, 2024. Parties traded 48 contract(s) at a $270.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $58.8K, with a price of $1225.0 per contract. There were 1473 open contracts at this strike prior to today, and today 688 contract(s) were bought and sold. 
• Regarding FHN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>), we observe a put option trade with neutral sentiment. It expires in 106 day(s) on February 21, 2025. Parties traded 154 contract(s) at a $21.00 strike. The total cost received by the writing party (or parties) was $28.4K, with a price of $185.0 per contract. There were 0 open contracts at this strike prior to today, and today 154 contract(s) were bought and sold. 
• For AXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), we notice a call option sweep that happens to be bullish, expiring in 316 day(s) on September 19, 2025. This event was a transfer of 62 contract(s) at a $390.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $457.0 per contract. There were 52 open contracts at this strike prior to today, and today 152 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFRM

COIN

FUTU

PYPL

TOST

UPST

10 Financials Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Information Technology sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$147.00</td>
<td>$95.3K</td>
<td>5.1K</td>
<td>39.3K</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$25.00</td>
<td>$36.3K</td>
<td>7.3K</td>
<td>19.5K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$422.50</td>
<td>$32.5K</td>
<td>5.6K</td>
<td>7.4K</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$250.00</td>
<td>$53.2K</td>
<td>4.6K</td>
<td>6.6K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.00</td>
<td>$420.6K</td>
<td>2.9K</td>
<td>4.7K</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$15.00</td>
<td>$39.7K</td>
<td>17.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>WULF</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$10.00</td>
<td>$34.0K</td>
<td>329</td>
<td>3.7K</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$35.00</td>
<td>$38.3K</td>
<td>9.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>UMC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.00</td>
<td>$39.5K</td>
<td>2.6K</td>
<td>2.4K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$200.00</td>
<td>$37.5K</td>
<td>10.1K</td>
<td>2.3K</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding NVDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on November 8, 2024. Parties traded 990 contract(s) at a $147.00 strike. This particular put needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $95.3K, with a price of $98.0 per contract. There were 5125 open contracts at this strike prior to today, and today 39381 contract(s) were bought and sold. 
• For SMCI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), we notice a call option sweep that happens to be bearish, expiring in 1 day(s) on November 8, 2024. This event was a transfer of 300 contract(s) at a $25.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $36.3K, with a price of $121.0 per contract. There were 7360 open contracts at this strike prior to today, and today 19547 contract(s) were bought and sold. 
• For MSFT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), we notice a call option sweep that happens to be bearish, expiring in 1 day(s) on November 8, 2024. This event was a transfer of 100 contract(s) at a $422.50 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $32.5K, with a price of $325.0 per contract. There were 5653 open contracts at this strike prior to today, and today 7465 contract(s) were bought and sold. 
• Regarding APP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), we observe a call option trade with bearish sentiment. It expires in 71 day(s) on January 17, 2025. Parties traded 25 contract(s) at a $250.00 strike. The total cost received by the writing party (or parties) was $53.2K, with a price of $2130.0 per contract. There were 4648 open contracts at this strike prior to today, and today 6624 contract(s) were bought and sold. 
• Regarding CORZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>), we observe a call option sweep with bearish sentiment. It expires in 161 day(s) on April 17, 2025. Parties traded 1717 contract(s) at a $17.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $420.6K, with a price of $245.0 per contract. There were 2917 open contracts at this strike prior to today, and today 4756 contract(s) were bought and sold. 
• Regarding CLSK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>), we observe a call option sweep with bullish sentiment. It expires in 8 day(s) on November 15, 2024. Parties traded 748 contract(s) at a $15.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $39.7K, with a price of $53.0 per contract. There were 17236 open contracts at this strike prior to today, and today 4049 contract(s) were bought and sold. 
• For WULF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>), we notice a call option trade that happens to be neutral, expiring in 161 day(s) on April 17, 2025. This event was a transfer of 200 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $170.0 per contract. There were 329 open contracts at this strike prior to today, and today 3725 contract(s) were bought and sold. 
• Regarding MARA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>), we observe a call option trade with bullish sentiment. It expires in 134 day(s) on March 21, 2025. Parties traded 243 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $38.3K, with a price of $158.0 per contract. There were 9184 open contracts at this strike prior to today, and today 2585 contract(s) were bought and sold. 
• Regarding UMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>), we observe a call option sweep with bearish sentiment. It expires in 8 day(s) on November 15, 2024. Parties traded 1314 contract(s) at a $7.00 strike. This particular call needed to be split into 52 different trades to become filled. The total cost received by the writing party (or parties) was $39.5K, with a price of $30.0 per contract. There were 2687 open contracts at this strike prior to today, and today 2424 contract(s) were bought and sold. 
• Regarding AAPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), we observe a call option sweep with bullish sentiment. It expires in 225 day(s) on June 20, 2025. Parties traded 10 contract(s) at a $200.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $37.5K, with a price of $3750.0 per contract. There were 10135 open contracts at this strike prior to today, and today 2358 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

CLSK

Core Scientific, Inc. - Class A Common Stock

CORZ

MARA

MSFT

NVDA

SMCI

WULF

10 Information Technology Stocks With Whale Alerts In Today's Session

Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) has started taking orders for its electric Gravity SUV <a target="_blank" href="https://www.benzinga.com/news/24/10/41617327/lucid-to-start-taking-orders-for-gravity-suv-next-week-but-only-for-premium-variant-priced-at-about" rel="noreferrer noopener">as planned</a>.
The Gravity will likely rival&nbsp;Tesla Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model X SUV. The company launched the configuration tool for its new Lucid Gravity Grand Touring, allowing customers to customize and order the vehicle on <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41807763/lucid-gravity-now-available-to-configure-and-order-on-the-lucid-motors-website" rel="noreferrer noopener">its website</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41807409/himax-q3-earnings-revenue-beats-forecast-ceo-highlights-growth-in-automotive-ai-oled-sectors-sets-c" rel="noreferrer noopener">Himax Q3 Earnings: Revenue Beats Forecast, CEO Highlights Growth in Automotive, AI, OLED Sectors, Sets Cautious Q4 Guidance</a>
Production for this advanced electric SUV model is slated to begin at the end of 2024.
The Lucid Gravity SUV combines luxury, spacious design, and range into a unique driving experience.
Lucid Gravity offers the space and utility of a full-size SUV within a midsize frame. This design accommodates up to seven passengers, blending functionality and luxury with a compact exterior that enhances maneuverability, the company said in the press release.
The Gravity lineup includes the Grand Touring variant, priced at $94,900, and the Touring model, expected to launch in late 2025, priced at $79,900.
The Grand Touring version delivers 828 horsepower and an impressive projected range of over 440 miles per charge.
The SUV includes Lucid's DreamDrive driver-assistance system as standard, with upgrades available through DreamDrive Premium and DreamDrive Pro for enhanced features like hands-free driving, adaptive lane change, and traffic light recognition.
The Gravity launch is critical for Lucid's future. Although the company has boosted Air sedan sales recently by lowering prices and introducing a more affordable trim, its sales remain far below projections made during its $4 billion reverse merger in 2021, TechCrunch <a target="_blank" href="https://techcrunch.com/2024/11/07/lucid-motors-starts-taking-orders-for-its-existential-gravity-suv/" rel="noreferrer noopener">reports</a>.
To support its financial reserves, Lucid has turned repeatedly to its majority owner, Saudi Arabia, for additional funding this year.
One of Lucid's main challenges is affordability; its vehicles exceed the federal EV tax credit price cap at the point of sale.
However, a $7,500 tax credit applies to leases—a benefit that depends on the federal tax credit remaining in place when President-elect Donald Trump takes office next year.
Lucid Group stock plunged over 45% year-to-date.
Price Action: LCID stock is up 3.99% at $2.21 at the last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41811828/epam-q3-earnings-beats-expectations-rising-margins-ceo-flags-neoris-acquisition" target="_blank" rel="noreferrer noopener">EPAM Q3 Earnings: Beats Expectations, Rising Margins, CEO Flags NEORIS Acquisition</a></li>
</ul>
Photo courtesy: Lucid

LCID

Lucid Opens Orders for New Gravity SUV, Taking Aim at Tesla's Model X

JP Morgan analyst Bryan Smilek maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Overweight and raises the price target from $303 to $360.

DUOL

JP Morgan Maintains Overweight on Duolingo, Raises Price Target to $360

JP Morgan analyst Drew Chamberlain maintains Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) with a Underweight and raises the price target from $16 to $17.

CTRI

JP Morgan Maintains Underweight on Centuri Holdings, Raises Price Target to $17

RBC Capital analyst Matthew Hedberg maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $202 to $230.

RBC Capital Maintains Outperform on PTC, Raises Price Target to $230

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Overweight and raises the price target from $21 to $22.

CLBT

JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $22

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and raises the price target from $15 to $16.

PCRX

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $16

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Fisker (NYSE:<a href="https://investorplace.com/stock-quotes/fsr-stock-quote/">FSR</a>) stock is moving on Monday after the electric vehicle (EV) company announced that it has secured an <a href="https://investors.fiskerinc.com/news/news-details/2024/Fisker-Announces-Receipt-of-Financing-Commitment-of-Up-to-150-Million-and-Provides-Business-Update/default.aspx">additional $150 million in funding</a>.



According to a press release from Fisker, the company&rsquo;s new funding comes from the holder of its 2025-dated convertible notes. It&rsquo;s also worth noting that this funding is being split into four tranches.



Fisker also mentions that this funding is only available if it meets certain conditions. Chief among these is the filing of the company&rsquo;s Form 10-K for 2023.



Investors will keep in mind that Fisker still has inventory from 2023 on hand. Combined with what has been produced in 2024, it has an excess inventory of over $200 million. The company is pausing production for six weeks starting today to align its inventory.



It&rsquo;s also worth mentioning that Fisker is still in talks with a large automaker for an investment. This has it hoping for funding to develop an EV platform with the manufacturer.



<h2>How This Affects FSR Stock Today</h2>



Despite news of the additional financing, shares of FSR stock are still falling on Monday. This has the stock down 12% this morning.



That drop for FSR stock comes alongside some 136 million shares changing hands. That&rsquo;s a massive surge in trading volume compared to the company&rsquo;s average of about 67 million shares.



Investors searching for more of the latest stock market stories are in luck!



We have all of the hottest stock market news ready to go on Monday! A few examples include what has shares of Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>), Xpeng&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/xpev-stock-quote/">XPEV</a>) and Ensysce Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/">ENSC</a>) stock moving today. All of that information is ready to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/nio-stock-ceo-william-li-says-second-gen-nio-phone-is-underway/">NIO Stock: CEO William Li Says Second-Gen Nio Phone Is Underway</a></li>



<li><a href="https://investorplace.com/2024/03/xpev-stock-alert-xpeng-pops-on-news-of-cheaper-ev-brand/">XPEV Stock Alert: Xpeng Pops on News of Cheaper EV Brand</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/ensc-stock-earnings-ensysce-biosciences-for-q4-of-2023/">ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/fsr-stock-the-150-million-reason-fisker-shares-are-moving-today/">FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today

Ensysce Biosciences GAAP EPS of -$0.55

Ensysce Biosciences regains Nasdaq compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ensysce Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/">ENSC</a>) just reported results for the first quarter of 2024.<ul><li>Ensysce Biosciences reported earnings per share of -55 cents. This was above the analyst estimate for EPS of -93 cents.</li><li>The company reported revenue of $305,722.</li><li>This was 23.57% worse than the analyst estimate for revenue of $400,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/ensc-stock-earnings-ensysce-biosciences-for-q1-of-2024/">ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ensysce Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ensc-stock-quote/">ENSC</a>) just reported results for the second quarter of 2024.<ul><li>Ensysce Biosciences reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -39 cents.</li><li>The company reported revenue of $181,797.</li><li>This was 39.40% worse than the analyst estimate for revenue of $300,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ensc-stock-earnings-ensysce-biosciences-for-q2-of-2024/">ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q2 2024

Ensysce Biosciences GAAP EPS of -$0.22 beats by $0.11

Ensysce wins $14M federal grant for lead pain therapy

Voxx International Corp., Trinity Biotech Plc, and Ensysce Biosciences are the 3 Penny Stocks to watch on August 29, based on&nbsp;TipRanks' Penny ...

3 Penny Stocks to Watch Now, 8/29/24

Ensysce Biosciences announces $5M concurrent offering, shares fall

Ensysce Biosciences receives non-compliance notice from Nasdaq

ENSC

TRIB

VOXX

Press Releases

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Biotech

Offerings

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Presenting at Upcoming Meetings

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Power Nickel Announces Major Copper Discovery as Gold Hits Historic High more stocks inside….

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

CFTN

DBGI

ENSCW

KAVL

PNPNF

STBX

ABVC BioPharma

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Carmell

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Eterna Therapeutics

Forte Biosciences

Galecto

GT Biopharma

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Mustang Bio

Moleculin Biotech

NKGen Biotech

Organovo Holdings

Plus Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Soligenix

Senti Biosciences

Vaccinex

Vincerx Pharma

Viracta Therapeutics, Inc. - Common Stock

Viracta Therapeutics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

Lake Street

WIIM

Ensysce Biosciences shares are trading higher after the company announced it received notice that it may continue its listing on the Nasdaq capital market.

Comments

Ensysce Biosciences

Ensysce Biosciences (ENSC) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル